Literature DB >> 16549226

Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.

Masahito Horiuchi1, Megumi Kimura, Miwa Tokumura, Nobuyoshi Hasebe, Tohko Arai, Kohji Abe.   

Abstract

beta-Lactam antibiotics have been suggested to have some degree of convulsive activity and neurotoxicity in experimental animals as well as in clinical situations. We examined the convulsive activities of a new carbapenem antibiotic, (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[(3S,5S)-5-[(sulfamoylamino)methyl]-3-pyrrolidinyl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxic acid monohydrate (doripenem) using several animals and compared them with beta-lactam antibiotics. In intravenous (IV) injection studies, imipenem/cilastatin, at 400/400mg/kg produced seizure discharges on electroencephalogram (EEG) accompanied with clonic convulsions in rats. Meropenem showed only wet dog shaking behavior at 200 and 400mg/kg. Doripenem caused no changes in the EEG and behavior in rats at 400mg/kg. Imipenem/cilastatin IV potentiated the pentylenetetrazol (PTZ)-induced convulsions in mice at 250/250 mg/kg, while meropenem, panipenem/betamipron, cefazolin or doripenem did not cause any marked effects at up to 500 mg/kg. In mouse intracerebroventricular (ICV) injection studies, imipenem, panipenem and cefazolin induced clonic convulsions in a dose-dependent manner in mice. Doripenem and meropenem did not induce convulsions at up to 100 microg/mouse. In dog ICV injection studies, imipenem produced generalized seizure discharge with clonic convulsions at 100 microg/dog. Meropenem also produced spikes or seizure discharges at 100, 300 and 1,000 microg/dog. However, doripenem had no effects on the EEG and behavior in dogs at any doses. In in vitro binding studies, imipenem, panipenem, cefazolin and meropenem inhibited [(3)H]muscimol binding to the GABA(A) receptor in mouse brain homogenates while doripenem did not cause any inhibition at up to 10mM. In addition, doripenem had no influence on the anti-convulsant actions of valproic acid in the PTZ- or bicuculine-induced convulsive model. These results clearly indicate that doripenem has no convulsive activity, suggesting that its neurotoxicity may be negligible in clinical use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16549226     DOI: 10.1016/j.tox.2006.02.004

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  19 in total

1.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2016-09-15       Impact factor: 5.790

2.  Penetration of intact blood-brain barrier by doripenem.

Authors:  K Margetis; E Dimaraki; G Charkoftaki; E Vryonis; S Markantonis; N Boutos; H Archontaki; D E Sakas; G Valsami; A Skoutelis
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

Review 3.  Neuropsychiatric Effects of Antimicrobial Agents.

Authors:  Nicholas Zareifopoulos; George Panayiotakopoulos
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

4.  Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates.

Authors:  C Betriu; M Gómez; F López-Fabal; E Culebras; I Rodríguez-Avial; J J Picazo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-04       Impact factor: 3.267

5.  Convulsive liability of cefepime and meropenem in normal and corneal kindled mice.

Authors:  Akihiro Tanaka; Kenshi Takechi; Shinichi Watanabe; Mamoru Tanaka; Katsuya Suemaru; Hiroaki Araki
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

6.  Doripenem (Doribax): the newest addition to the carbapenems.

Authors:  Nickie D Greer
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-07

Review 7.  Management of meningitis due to antibiotic-resistant Acinetobacter species.

Authors:  Baek-Nam Kim; Anton Y Peleg; Thomas P Lodise; Jeffrey Lipman; Jian Li; Roger Nation; David L Paterson
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

8.  Use of doripenem and risk of seizure and renal impairment in US hospitalized patients: a retrospective cohort study.

Authors:  Scott Chavers; Glenn Magee; Dorothy Baumer; Helen Pai
Journal:  Ther Adv Drug Saf       Date:  2015-12-14

Review 9.  Overview of seizure-inducing potential of doripenem.

Authors:  George G Zhanel; Nzeera Ketter; Ethan Rubinstein; Ian Friedland; Rebecca Redman
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Characteristics of doripenem: a new broad-spectrum antibiotic.

Authors:  Francisco Alvarez-Lerma; Santiago Grau; Olivia Ferrández
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.